However, restoration of BRCA1/2 function due to secondary mutations has been recognized as the mechanism for acquired resistance to Cisplatin and PARP (Poly (ADP-ribose) polymerase) inhibitors in these cancer cells3, 4, 5, 6. This evidence concerns the gene BRCA1 and cancer.